Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors

S. I. Labidi-Galy, A. Clauss, V. Ng, S. Duraisamy, K. M. Elias, H. Y. Piao, E. Bilal, R. A. Davidowitz, Y. Lu, G. Badalian-Very, B. Györffy, U. B. Kang, S. Ficarro, S. Ganesan, G. B. Mills, J. A. Marto, R. Drapkin

    Research output: Contribution to journalArticle

    17 Scopus citations

    Abstract

    High-grade serous ovarian carcinoma (HGSOC) and basal-like breast cancer (BLBC) share many features including TP53 mutations, genomic instability and poor prognosis. We recently reported that Elafin is overexpressed by HGSOC and is associated with poor overall survival. Here, we confirm that Elafin overexpression is associated with shorter survival in 1000 HGSOC patients. Elafin confers a proliferative advantage to tumor cells through the activation of the MAP kinase pathway. This mitogenic effect can be neutralized by RNA interference, specific antibodies and a MEK inhibitor. Elafin expression in patient-derived samples was also associated with chemoresistance and strongly correlates with bcl-xL expression. We extended these findings into the examination of 1100 primary breast tumors and six breast cancer cell lines. We observed that Elafin is overexpressed and secreted specifically by BLBC tumors and cell lines, leading to a similar mitogenic effect through activation of the MAP kinase pathway. Here too, Elafin overexpression is associated with poor overall survival, suggesting that it may serve as a biomarker and therapeutic target in this setting.

    Original languageEnglish (US)
    Pages (from-to)299-309
    Number of pages11
    JournalOncogene
    Volume34
    Issue number3
    DOIs
    StatePublished - Jan 15 2015

    Keywords

    • Basal-like breast cancer
    • Elafin
    • MAP kinase
    • Mitogen
    • Ovarian cancer

    ASJC Scopus subject areas

    • Molecular Biology
    • Genetics
    • Cancer Research

    Fingerprint Dive into the research topics of 'Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors'. Together they form a unique fingerprint.

  • Cite this

    Labidi-Galy, S. I., Clauss, A., Ng, V., Duraisamy, S., Elias, K. M., Piao, H. Y., Bilal, E., Davidowitz, R. A., Lu, Y., Badalian-Very, G., Györffy, B., Kang, U. B., Ficarro, S., Ganesan, S., Mills, G. B., Marto, J. A., & Drapkin, R. (2015). Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene, 34(3), 299-309. https://doi.org/10.1038/onc.2013.562